Summit Therapeutics Shares Gain 5.8% Following Jefferies Buy Upgrade

Summit Therapeutics (SMMT) shares rose 5.8% Tuesday after Jefferies upgraded the stock from Hold to Buy and increased its price target from $15 to $25. This change follows analyst optimism regarding the company’s lead drug candidate, ivonescimab, and the upcoming HARMONi-3 clinical trial data anticipated in late 2026.

"The firm believes progression-free survival is likely to achieve statistical significance barring outlier degradation from China to the global trial, with most scenarios driving confidence in a downstream overall survival win," said Faisal Khurshid, analyst at Jefferies, in a note to clients.

Clinical Expectations and Hazard Ratios

The upgrade depends on specific performance benchmarks for ivonescimab. Jefferies projects a progression-free survival (PFS) hazard ratio of 0.65 to 0.70 for the drug. In clinical oncology trials, a hazard ratio below 1.0 indicates that the treatment group is experiencing the event, which is disease progression, at a lower rate than the control group. Khurshid noted that a ratio below 0.75 would be considered a clinical success for the program.

Analyst Consensus and Market Outlook

Jefferies joins other firms maintaining positive outlooks on Summit Therapeutics as the company approaches key data milestones. Current analyst coverage includes:

• Guggenheim: Maintains a Buy rating with a $38 price target.
• UBS: Maintains a Buy rating with a $33 price target.
• Cantor Fitzgerald: Maintains an Overweight rating.
• H.C. Wainwright: Maintains a Neutral rating.

For investors, the primary focus remains the translation of ivonescimab's efficacy from previous trials in China to the broader global patient population in the HARMONi-3 study. Replicating these results is the critical factor for the drug's eventual regulatory approval and commercial viability in international markets.